Assessment of Serum Soluble Toll-like Receptor-4 and Interleukin-8 as Biomarkers in Patients with Breast Cancer

Ikram Khazal Al-Hasso

doi:10.54133/ajms.v6i1.568

المؤلفون

Ikram Khazal Al-Hasso Department of Microbiology, College of Medicine, Mosul University, Nineveh, Iraq https://orcid.org/0000-0003-3580-3455

DOI:

https://doi.org/10.54133/ajms.v6i1.568

الكلمات المفتاحية:

Biomarker، Breast cancer، Interleukin-8، Toll-like receptors

الملخص

Background: Chemokines and toll-like receptors (TLR) have a synergistic role in the initiation and progression of breast cancer. TLR-4 is involved in the invasiveness of cancerous cells. Interleukin-8 (IL-8) has a significant role in boosting the angiogenesis and growth of cancer cells. Objective: To measure the level of soluble TLR-4 and interleukin-8 in patients with breast cancer and to study the possibility of using them as diagnostic and prognostic biomarkers in these patients. Methods: The study enrolled a total of 200 female subjects: 100 patients who were diagnosed with breast cancer and 100 healthy controls. Soluble TLR-4 and IL-8 levels in the blood were evaluated by the enzyme-linked immunosorbent assay. Results: upregulated levels of soluble TLR-4 as well as interleukin-8 in individuals with breast cancer compared to controls (5.79 vs. 1.01 ng/ml for TLR-4 and 29.1 vs. 7.1 pg/ml for IL-8). The concentration of soluble Toll-like receptor-4 besides interleukin-8 is significantly higher in stage IV than in other stages. A substantial increase in these biomarkers in grade 3 was detected compared to other grades. ROC curves show that both biomarkers were useful in differentiating between healthy females and those who have breast cancer. Conclusions: High concentrations of soluble TLR-4 as well as IL-8 have been linked to advanced stages of breast cancer, and these markers were effective in detecting the disease and predicting its prognosis.

التنزيلات

بيانات التنزيل غير متوفرة بعد.

المراجع

Al-Hashimi MMY. Trends in Breast Cancer Incidence in Iraq During the Period 2000-2019. Asian Pacific J Cancer Prevent. 2021;22(12):3889-3896. doi: 10.31557/APJCP.2021.22.12.3889.

Armant MA, Fenton MJ. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol. 2002;3(8):3011. doi: 10.1186/gb-2002-3-8-reviews3011.

El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: an overview. Bull Nat Res Centre. 2019;43(1):187. PMID: 34552981.

Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. BioMed Res Int. 2021;2021:1157023. doi: 10.1155/2021/1157023.

Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, et al. Expression profile of Toll‑like receptors in human breast cancer. Mol Med Rep. 2020;21(2):786-794. doi: 10.3892/mmr.2019.10853.

Khadem alhosseini M, Arababadi MK. Toll-like receptor 4 and breast cancer: an updated systematic review. Breast Cancer (Tokyo, Japan). 2019;26(3):265-271. doi: 10.1007/s12282-018-00935-2.

Hao B, Chen Z, Bi B, Yu M, Yao S, Feng Y, et al. Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis. Oncotarget. 2018;9(16):13088-13099. doi: 10.18632/oncotarget.24178.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6-15. doi: 10.1038/s41416-018-0328-y.

Cheng D, Hao Y, Zhou W, Ma Y. Positive association between Interleukin-8 -251A > T polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Cancer Cell Int. 2013;13(1):100. doi: 10.18632/oncotarget.18220.

Zuccari DA, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochemica. 2012;114(6):571-576. doi: 10.1016/j.acthis.2011.10.007.

Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12(4):375-91. doi: 10.1016/s1359-6101(01)00016-8

Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15(4):210. doi: 10.1186/bcr3436.

Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis. 2008;29(6):1148-1156. doi: 10.1093/carcin/bgn109.

Teichgraeber DC, Guirguis MS, Whitman GJ. Breast cancer staging: Updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. Am J Roentgenol. 2021;217(2):278-290. PMID: 33594908.

Edechi CA, Ikeogu N, Uzonna JE, Myal Y. Regulation of immunity in breast cancer. Cancers. 2019;11(8). doi: 10.3390/cancers11081080.

Wang X, Yu X, Wang Q, Lu Y, Chen H. Expression and clinical significance of SATB1 and TLR4 in breast cancer. Oncol Lett. 2017;14(3):3611-3615. doi: 10.3892/ol.2017.6571.

Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29(1):92. doi: 10.1186/1756-9966-29-92.

Haricharan S, Brown P. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci U S A. 2015;112(25):E3216-3225. doi: 10.1073/pnas.1420811112.

Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G. Significance of TLR4/MyD88 expression in breast cancer. Int J Clin Exp Pathol. 2015;8(6):7034-7039. PMID: 26261595.

Yang H, Wang B, Wang T, Xu L, He C, Wen H, et al. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PloS One. 2014;9(10):e109980. doi: 10.1371/journal.pone.0109980.

Wang YC, wang ZH, Yen JH, Shen YC, Shen TC, Chang WS, et al. The contribution of interleukin-8 Rs4073 genotypes to triple negative breast cancer risk in Taiwan. Anticancer Res. 2022;42(8):3799-3806. doi: 10.21873/anticanres.15870.

Mohsin SAM, Al-Thwani AN. Clinical importance of interleukin-8 concentration in Iraqi breast cancer patients. Iraqi J Biotechnol. 2012;11(1):133-140.

Green AR, Green VL, White MC, Speirs V. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer. 1997;72(6):937-941. doi: 10.1002/(sici)1097-0215(19970917)72:6<937::aid-ijc3>3.0.co;2-q.

Ahmed OI, Adel AM, Diab DR, Gobran NS. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol. 2006;13(2):61-68. PMID: 18689272.

Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 2000;6(7):2735-2740. PMID: 10914718.

Matsui T, Ojima A, Higashimoto Y, Taira J, Fukami K, Yamagishi I. Pigment epithelium‑derived factor inhibits caveolin‑indced interleukin‑8 gene expression and proliferation of human prostate cancer cells. Oncol Lett. 2015;10(4):2644-2648. doi: 10.3892/ol.2015.3568.

Van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol. 2002;116(1):173-177. doi: 10.1046/j.1365-2141.2002.03245.x.

Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10(21):7157-7162. PMID: 15534087.

Milovanović J, Todorović-Raković N, Radulovic M. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer. Cytokine. 2019;118:93-98. PMID: 29482885.

Miller L, Kurtzman S, Wang Y, Anderson K, Lindquist R, Kreutzer D. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 1998;18(1A):77-81. PMID: 9568059.

Tan PH, Chia SS, Toh SL, Goh JC, Nathan SS. The dominant role of IL-8 as an angiogenic driver in a three-dimensional physiological tumor construct for drug testing. Tissue Engineer Part A. 2014;20(11-12):1758-1766. doi: 10.1089/ten.TEA.2013.0245.

Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71(15):5296-5306. doi: 10.1158/0008-5472.can-11-0156.

Todorović-Raković N, Milovanović J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013;33(10):563-570. PMID: 23697558.

Sheikhpour R. The role of interleukin-8 and its mechanism in patients with breast cancer: Its relation with oxidative stress and estrogen receptor. Int J Cancer Manag. 2017;10(9):e8791. doi: 10.5812/ijcm.8791.